Incyte (MEX:INCY) Owner Earnings per Share (TTM): 130.05 (As of Jun. 2026) — 222% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:INCY Incyte Corp MEX:INCY
84 GF Score
Price MXN2,036.00
GF Value MXN1,741.09
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Incyte Owner Earnings per Share (TTM)?

Incyte MEX:INCY 84 Owner Earnings per Share (TTM) is 130.05 as of Jun. 2026, which is 222% above its 10-year median of 40.39. GuruFocus rates MEX:INCY with a GF Score™ of 84/100 and a GF Value™ of MXN1,741.09 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 207 Biotechnology companies, Incyte ranks better than 65.7% on this metric.

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Incyte's Owner Earnings per Share (TTM) ended in Jun. 2026 was MXN130.05. It's Price-to-Owner-Earnings ratio for today is 15.66.


The historical rank and industry rank for Incyte's Owner Earnings per Share (TTM) or its related term are showing as below:

MEX:INCY' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 14.8   Med: 40.39   Max: 509.41
Current: 15.66


During the past 13 years, the highest Price-to-Owner-Earnings ratio of Incyte was 509.41. The lowest was 14.80. And the median was 40.39.


MEX:INCY's Price-to-Owner-Earnings is ranked better than
65.7% of 207 companies
in the Biotechnology industry
Industry Median: 25.64 vs MEX:INCY: 15.66

Incyte's Earnings per Share (Diluted) for the three months ended in Jun. 2026 was MXN49.03. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was MXN140.33. It's PE Ratio (TTM) ratio for today is 14.51.

Incyte's EPS without NRI for the three months ended in Jun. 2026 was MXN53.92. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2026 was MXN160.16. It's PE Ratio without NRI ratio for today is 12.71.


Be Aware

Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.

Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.


Incyte Owner Earnings per Share (TTM) Related Terms


Incyte Owner Earnings per Share (TTM) Historical Data

* Premium members only.

The historical data trend for Incyte's Owner Earnings per Share (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Incyte Owner Earnings per Share (TTM) Chart

Incyte Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Owner Earnings per Share (TTM)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 39.25 51.84 21.27 9.27 89.67

Incyte Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Owner Earnings per Share (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 56.19 85.09 89.67 103.15 116.58

MEX:INCY vs INSM, BNTX, ROIV: Owner Earnings per Share (TTM) Comparison

For the Biotechnology subindustry, Incyte's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Incyte Price-to-Owner-Earnings vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Incyte's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Incyte's Price-to-Owner-Earnings falls into.


MEX:INCY
84GF Score
Incyte Corp MEX:INCY
Owner Earnings per Share (TTM) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Incyte Owner Earnings per Share (TTM) Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

To make it simple, then you will have:

Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)

Incyte's Owner Earnings per Share (TTM) Calculation:

TTM / Last Quarter Average of Last 20 Quarters
Net Income 28,858
Depreciation, Depletion and Amortization 1,764
Change In Deferred Tax 5,681
5Y Average of Maintenance Capital Expenditure 1,050
Change In Working Capital -5,811
Shares Outstanding (Diluted Average) 208

1. Start with "Net Income" from income statement. Incyte's Net Income for the trailing twelve months (TTM) ended in Jun. 2026 was MXN28,858 Mil.

2. "Depreciation, Depletion and Amortization" is from cashflow statement. Incyte's Depreciation, Depletion and Amortization for the trailing twelve months (TTM) ended in Jun. 2026 was MXN1,764 Mil. This needs to be added back because company does not actually need to pay cash for it. It is a non-cash item.

3. Other non-cash charges usually include "Stock Based Compensation" and "Change In Deferred Tax":
However, to be conservative, GuruFocus will not add Stock Based Compensation back to net income. Incyte's Change In Deferred Tax for the trailing twelve months (TTM) ended in Jun. 2026 was MXN5,681 Mil.

4. Average maintenance capital expenditure over a business/industry cycle: 5-Year Average Maintenance Capital Expenditure = MXN1,050 Mil

It is usually best to take a long-term average of maintenance capital expenditure. Ideally this would be as long as 10 years and include at least one economic downturn. However, since many companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year maintenance capital expenditure.

The following shows how to get maintenance capital expenditure.

First, calculate the revenue change regarding to the previous quarter. If the revenue decreased from the previous quarter, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous quarter, then calculate the percentage of Net PPE as of corresponding Revenue.
Growth Capital Expenditure = Percentage of Property, Plant and Equipment as of corresponding Revenue * Revenue Increase
Third, calculate Capital Expenditure (positive) - Growth Capital Expenditure.
If [Capital Expenditure (positive) - Growth Capital Expenditure] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - Growth Capital Expenditure] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - Growth Capital Expenditure.
Fourth, get the average of the 5 years maintenance capital expenditure.

Incyte's 5-Year Average Maintenance Capital Expenditure = MXN1,050 Mil

5. "Change In Working Capital" is from cashflow statement. Incyte's Change In Working Capital for the trailing twelve months (TTM) ended in Jun. 2026 was MXN-5,811 Mil.
Note: GuruFocus' Change in Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And sometimes it includes non-current parts of assets and liabilities.

6. Incyte's Shares Outstanding (Diluted Average) for the months ended in Jun. 2026 was 208.216 Mil.

Incyte's Onwer Earnings Per Share for Jun. 2026 is calculated as:

Owner Earnings per Share (TTM)
=( Net Income+Depreciation, Depletion and Amortization+Change In Deferred Tax
=( 28857.85 +1763.69+5680.883
-5Y Avg of Maintenance CAPEX+Change In Working Capital )/Shares Outstanding (Diluted Average)
-1050.2664648753+-5810.981)/208.216
=130.05

Price-to-Owner-Earnings=Current Price/Owner Earnings per Share (TTM)
=2036.00/130.05
=15.66

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Owner Earnings per Share (TTM) of 130.05 mean?
Incyte (MEX:INCY) has a Owner Earnings per Share (TTM) of 130.05 as of Jun. 2026. Warren Buffett defined owner earnings as reported earnings plus depreciation less average maintenance capital expenditure. View historical data on Incyte. This is 222% above median its historical median of 40.39. Over the past decade, Incyte's Owner Earnings per Share (TTM) has ranged from 14.80 to 509.41. According to the industry distribution chart, Incyte ranks #71 out of 207 companies in the Biotechnology industry, placing it in the top 34.3%.
Is Incyte's Owner Earnings per Share (TTM) too high?
Incyte's current Owner Earnings per Share (TTM) of 130.05 is 222% above median its 10-year median of 40.39. Over the past 10 years, this metric has ranged from a low of 14.80 to a high of 509.41. The Biotechnology industry median Owner Earnings per Share (TTM) is 25.64. Incyte's value of 130.05 is 407.2% above this industry median. Based on the distribution chart, Incyte ranks #71 out of 207 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Incyte has a GF Score™ of 84/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Incyte's Owner Earnings per Share (TTM) compare to INSM and BNTX?
According to the Biotechnology industry distribution chart, Incyte ranks #71 out of 207 companies for Owner Earnings per Share (TTM). This puts Incyte in the upper half of its industry. The industry median Owner Earnings per Share (TTM) is 25.64. Incyte's value of 130.05 is 407.2% above this benchmark. Historically, Incyte's own Owner Earnings per Share (TTM) has ranged from 14.80 to 509.41 over the past decade. While the company's 10-year median is 40.39 vs. the industry median of 25.64, Incyte has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Owner Earnings per Share (TTM) for a Biotechnology company?
The median Owner Earnings per Share (TTM) among Biotechnology companies is 25.64, based on 207 companies in the industry. Companies in the top quartile (top 25%) have a Owner Earnings per Share (TTM) significantly above this median, while those in the bottom quartile fall well below. However, Owner Earnings per Share (TTM) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Incyte's current Owner Earnings per Share (TTM) of 130.05 is 407.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Owner Earnings per Share (TTM) mean?
A high Owner Earnings per Share (TTM) can signal that a stock is expensive relative to its fundamentals. Warren Buffett defined owner earnings as reported earnings plus depreciation less average maintenance capital expenditure. View historical data on Incyte. For the Biotechnology industry, the median Owner Earnings per Share (TTM) is 25.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Incyte's current Owner Earnings per Share (TTM) is 130.05, which is 222% above median its own 10-year median of 40.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Incyte stock overvalued right now?
Based on GuruFocus' analysis, Incyte (MEX:INCY) is currently considered Modestly Overvalued. The stock's GF Value™ is MXN1,741.09, compared to a current price of MXN2,036.00 — trading 16.9% above its estimated fair value. The current Owner Earnings per Share (TTM) is 130.05, which is 222% above median its 10-year median of 40.39 and 407.2% above the Biotechnology industry median of 25.64. Incyte's overall GF Score™ is 84/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Owner Earnings per Share (TTM) calculated?
Owner Earnings per Share (TTM) is calculated from a company's financial statements. For Incyte (MEX:INCY), the current Owner Earnings per Share (TTM) is 130.05 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Incyte (MEX:INCY) Overvalued in 2026?

Based on GuruFocus' analysis, Incyte stock appears to be overvalued. The current stock price of MXN2,036.00 is trading 16.9% above its estimated GF Value™ of MXN1,741.09. GuruFocus considers Incyte to be Modestly Overvalued.

Key valuation signals for MEX:INCY:

  • Owner Earnings per Share (TTM): 130.05 (222% above median its 10-year median of 40.39)
  • GF Value™: MXN1,741.09 vs. price of MXN2,036.00 (16.9% above fair value)
  • GF Score™: 84/100 with 4 warning signs
  • Industry Position: 407.2% above the Biotechnology median (#71 of 207)

No single metric tells the full story. See the MEX:INCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Incyte Business Description

Address 1801 Augustine Cut-Off, Wilmington, DE, USA, 19803
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
84GF Score

Get the complete analysis for MEX:INCY

Owner Earnings per Share (TTM) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN2,036.00
Price
MXN1,741.09
GF Value